Hervé Hoppenot, Incyte CEO (Jeff Rumans)
Incyte cuts final trial for PI3K drug more than a year after yanking accelerated approval filing
The “challenging regulatory landscape” surrounding the class of drugs known as PI3K inhibitors has pushed Incyte to shut down the final trial in its PI3K …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.